- cafead Sep 30, 2019 at 10:52: AM
via Avanir’s no good, awful, simply terrible week came to a disastrous end last Friday as the Otsuka subsidiary was forced to report that its second Phase III trial for a new-and-improved version of its commercial drug had failed in treating Alzheimer’s dementia — likely scuttling any future it may have had in the most difficult of all diseases.
article source
article source